REG - Physiomics PLC - Board Changes

PhysiomicsAnnouncement

22/01/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240122:nRSV1971Aa&default-theme=true

RNS Number : 1971A  Physiomics PLC  22 January 2024

22 January 2024

 

Physiomics plc

("Physiomics" or "the Company")

 

Board Changes

 

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models
to support the development of cancer treatment regimens and personalised
medicine solutions, announces changes to its board of directors.  The Company
is pleased to announce that Dr Jim Millen has been appointed Non-Executive
Chairman and Dr Peter Sargent, currently Chief Operating Officer, has been
appointed as Chief Executive Officer and a director of the Company with
immediate effect.

Dr Sargent joined the Company in September 2023 as Chief Operating Officer and
has quickly proved invaluable in helping to drive the Company's business
development agenda, supporting the technical team and developing our overall
strategy.  He has worked closely with Dr Millen over the last five months and
has already taken on responsibility for many of the activities that will be at
the core of his new, expanded role.  Dr Millen will remain closely involved
with the Company as Non-Executive Chairman and will be available as needed to
provide additional support to the executive team during the transition period
and on an ongoing basis.

Dr Jim Millen has acted as Executive Chairman and Chief Executive Officer of
Physiomics since February 2022, and the changes announced today, together with
the appointment of two Non-Executive Directors in 2022, completes a
restructuring of the leadership team which the Board believes provides a
strong platform for the growth of the business and more closely aligns the
structure of the Board with the guidelines of the QCA Corporate Governance
Code

Dr Jim Millen and Dr Pete Sargent will provide a brief update on these Board
changes via Investor Meet Company on 29 January 2024 at 1:00 pm GMT, during
which they would be happy to take questions relating to the changes announced
today.  The presentation is open to all existing and potential shareholders.
Questions can be submitted pre-event via your Investor Meet Company dashboard
up until 9:00 am GMT the working day before the meeting or at any time during
the live presentation.  Investors can sign up to Investor Meet Company for
free and add to meet Physiomics plc via:
https://www.investormeetcompany.com/physiomics-plc/register-investor
(https://www.investormeetcompany.com/physiomics-plc/register-investor) .
Investors who already follow the Company on the Investor Meet Company platform
will automatically be invited.

 

Dr Jim Millen, Chairman, commented:

"Since joining the Company last September, Pete has demonstrated to me and the
Board that he has the skills, experience, attitude and vision to help us
achieve our strategic goals.  I look forward with optimism to what we can
achieve under Peter's executive leadership and to continuing to work closely
with him in our new roles."

 

Dr Peter Sargent, CEO, commented:

"I am thrilled to take on the role of CEO and director of Physiomics. Having
had time to get to know the business and meet many of our clients and partners
over these last few months, I can see many exciting opportunities ahead for
us. I look forward to speaking to shareholders next week and over the course
of 2024."

 

Further information on Dr Sargent:

Prior to joining Physiomics in September 2023, Dr Sargent held a senior
management role at global consultancy business Syneos Health Inc (NASDAQ:
SYNH), leading large teams of professionals and servicing a variety of clients
in the biopharmaceuticals space.  Among his other previous roles, Dr Sargent
has also been Head of Business Development for the UK's National Institute for
Health and Care Research (NIHR), leading a team supporting global life science
businesses access to funding and research infrastructure in the UK.

 

The following details in relation to the appointment of Dr Sargent are
disclosed in accordance with AIM Rule 17 and Schedule 2(g) of the AIM Rules:

Peter Joseph Sargent (aged 45) has not held any directorships and/or
partnerships in the past five years.

There is no further information to be disclosed in relation to Dr Sargent's
appointment pursuant to AIM Rule 17 or Schedule Two, paragraph (g) (i)-(viii)
of the AIM Rules for Companies.

 

 

Enquiries:

 

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

This announcement is released by Physiomics plc and contains inside
information for the purposes of Article 7 of the Market Abuse Regulation (EU)
596/2014 (MAR), and is disclosed in accordance with the Company's obligations
under Article 17 of MAR.

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models
to support the development of cancer treatment regimens and personalised
medicine solutions. The Company's Virtual Tumour™ technology uses computer
modelling to predict the effects of cancer drugs and treatments to improve the
success rate of drug discovery and development projects while reducing time
and cost. The predictive capability of Physiomics' technologies have been
confirmed by over 100 projects, involving over 50 targets and 75 drugs, and
has worked with clients such as Merck KGaA, Astellas, Merck & Co and
Bicycle Therapeutics.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAGPUMCGUPCGCR